Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
复制标题
DOI：
--
复制
发表时间：
1997-08
期刊：
影响因子：
11.2
通讯作者：
A. Bosserhoff;M. Kaufmann;B. Kaluza;I. Bartke;H. Zirngibl;R. Hein;Wilhelm Stolz;R. Buettner
中科院分区：
文献类型：
--
作者：
A. Bosserhoff;M. Kaufmann;B. Kaluza;I. Bartke;H. Zirngibl;R. Hein;Wilhelm Stolz;R. Buettner
黑色素瘤抑制活性（MIA）以前是作为一种小的可溶性蛋白分泌的恶性黑色素瘤细胞系在体外分离。在体内，黑素细胞肿瘤中高度限制的表达模式被确定。因此，我们通过非放射性ELISA定量测定血清MIA蛋白水平，并研究MIA是否为恶性黑色素瘤患者提供了一个临床有用的参数。在这里，我们报告了13%和23%的I期和II期疾病患者的MIA血清水平增强，III期或IV期疾病患者的MIA血清水平增强。与S-100和可溶性细胞间粘附分子1血清水平相比，MIA是这些患者中最敏感的标志物。IV期疾病的治疗反应与MIA血清水平的变化相关。在随访期间，重复测量350例有I期或II期黑色素瘤病史的患者的血清，我们检测到32例患者出现阳性MIA值。在血清分析时，其中15例发生转移，1例在6个月后出现转移性疾病。相反，在6-12个月的随访期间，MIA血清水平正常的患者均未发生转移。总之，MIA代表了一种新的系统性恶性黑色素瘤的血清标志物，在目前可用的标志物中显示出最高的灵敏度和特异性。有用的临床应用包括原发性黑色素瘤的分期，在随访期间检测从局部到转移性疾病的进展，以及监测晚期黑色素瘤的治疗。
Melanoma-inhibiting activity (MIA) was isolated previously as a small soluble protein secreted from malignant melanoma cell lines in vitro. In vivo, highly restricted expression patterns in melanocytic tumors were identified. We therefore quantitated serum levels of MIA protein by means of a nonradioactive ELISA and investigated whether MIA provides a clinically useful parameter in patients with malignant melanomas. Here, we report enhanced MIA serum levels in 13 and 23% of patients with stage I and II disease, respectively, and in 100% with stage III or IV disease. Compared with S-100 and soluble intercellular adhesion molecule 1 serum levels in these patients, MIA was the most sensitive marker. Response to therapy in stage IV disease correlated with changes in MIA serum levels. Measuring repeatedly sera of 350 patients with a history of stage I or II melanoma during follow-up, we detected 32 patients developing positive MIA values. At the time of serum analysis, 15 of them had developed metastases, and one presented with metastatic disease 6 months later. In contrast, none of the patients with normal MIA serum levels developed metastases during the follow-up period of 6-12 months. In conclusion, MIA represents a novel serum marker for systemic malignant melanoma revealing the highest sensitivity and specificity among currently available markers. Useful clinical applications include staging of primary melanomas, detection of progression from localized to metastatic disease during follow-up, and monitoring therapy of advanced melanomas.